Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pipelines, Not the Bottom Line, Define 2012 For Investors

Executive Summary

More than two dozen biotechs offer 2x returns in 2012, as investors pin their hopes on some hematology oncology and CNS plays. Investors think the party may continue into next year, but perhaps not so giddily.

Advertisement

Related Content

Ibrutinib Results Suggest Potential To Shake Up CLL Market
Acadia Now Has The Cash To Finish Phase III On Its Own
Interferon-Free Hepatitis C Regimens Within Reach
Biogen Reports Progress In Late-Stage Programs, Plus Some Bumps In The Road
Sarepta’s Eteplirsen and FDA’s “Breakthrough Therapy” Designation: A Perfect Fit?
Amgen Gobbles Up Micromet In $1.16 Billion BiTE

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054998

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel